德林控股(01709.HK)訂條款書 擬以股份互換方式投資富龍拓穩定幣業務合作
德林控股(01709.HK)宣布與香港科技公司富龍顧問達成戰略合作,簽訂一份不具法律約束力的條款書,將透過股份互換方式投資富龍,代價為6,000萬元。富龍將申請香港穩定幣牌照,取得該牌照後雙方預料會拓展穩定幣應用及業務合作。
德林控股表示,富龍或發行與離岸人民幣掛鉤的穩定幣,該穩定幣將完全由優質流動資產支持,並由受監管託管人保障,預期投資富龍令公司能夠直接進入快速增長的穩定幣領域。
目前交易僅為雙方對建議戰略合作及股份互換的初步共識,尚待進一步協商、盡職調查及簽立正式法律文件,並須獲證監及金管局的監管及合規批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.